Sort   by:  
 Page size 
MetabolomicsNon-invasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer
Lung cancer remains the most common cause of cancer deaths worldwide, yet there is currently a lack of diagnostic noninvasive biomarkers that could guide treatment decisions. Small molecules (<1500 Da) were measured in urine collected from 469 lung cancer patients and 536 population controls using u...
2014-05-06 | MTBLS28 | MetaboLights
MetabolomicsDistinct metabolic profiles in lung adenocarcinomas presenting as solid or ground-glass opacities

Metabolomic profiling provides real-time insights into tissue physiology and upstream molecular events. Despite its potential in cancer research, large-scale integrative studies in lung adenocarcinoma (LUAD) remain scarce. We analyzed 262 tissue samples from 165 LUAD patients using metabolomic, t...

2025-12-23 | MTBLS13565 | MetaboLights
MetabolomicsA blood-based metabolic signature for earlier detection of lung cancer

Metabolomic profiling was applied to 1,259 sera collected within five years of a lung cancer diagnosis and 8,470 non-case sera from ever-smoker participants in the Prostate Lung Colorectal and Ovarian (PLCO) Study to identify metabolic signatures for the earlier detection of lung cancer. We devel...

2026-08-20 | MTBLS15406 | MetaboLights
MetabolomicsTemporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment
Lung cancer causes more deaths in men and women than any other cancer related disease. Currently, few effective strategies exist to predict how patients will respond to treatment. We evaluated the serum metabolomic profiles of 25 lung cancer patients undergoing chemotherapy ± radiation to evaluate t...
2017-01-19 | MTBLS200 | MetaboLights
TranscriptomicsErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor Growth and Metastasis [expression]
Lung cancer remains the leading cause of cancer death. Genome sequencing of lung tumors from patients with Squamous Cell Carcinoma has identified SMAD4 to be frequently mutated. Here we used a novel mouse model to determine the molecular mechanisms regulated by loss of Smad4 which lead to lung cance...
ORGANISM(S): Mus musculus 
2015-03-05 | E-GEOD-57133 | biostudies-arrayexpress
MetabolomicsTargeting GSTZ1 sensitizes KRASG12C-mutant lung cancer cells by overcoming glutathione and glycolysis pathway rewiring

KRAS mutations are prevalent in lung cancer, but KRAS G12C inhibitors exhibit limited efficacy, partly due to metabolic adaptations, such as enhanced glutathione metabolism and increased glycolysis. Glutathione S-Transferase Zeta 1 (GSTZ1) is a metabolic enzyme that regulates cell metabolism. How...

2026-05-15 | MTBLS12791 | MetaboLights
MetabolomicsCombined metabolomics with transcriptomics reveals important serum biomarkers correlated with lung cancer proliferation through calcium signaling pathway

Lung cancer (LC) is still one of the most deadly cancers in the world, but there is a lack of non-invasive biomarkers to assist diagnosis and guide treatment. Herein, untargeted serum metabolomics of 57 LC patients and 59 HC people was performed based on gas chromatography-mass spectrography (GC-...

2025-04-29 | MTBLS1517 | MetaboLights
MetabolomicsNon-targeted metabolomics reveals diagnostic biomarker in the plasma of patients with lung cancer

Lung cancer are malignant tumors with high incidence and mortality rates, and a 5-year survival rate that depends on the stage at the time of diagnosis. Screening methods for lung cancer are becoming increasingly diverse, but existing approaches lack sensitivity or specificity for early lesions, ...

2025-09-13 | MTBLS12985 | MetaboLights
MetabolomicsTargeting secreted MDK-mediated tryptophan/kynurenine metabolism enhances DLL3 CAR T therapy for SCLC

Small cell lung cancer (SCLC) exhibits profound immunometabolic suppression that impairs antigen presentation and constrains immunotherapy efficacy. Through integrated multi-omics analyses of primary human SCLC tumors, we identified midkine (MDK) as a dominant tumor-secreted driver of immune evas...

2026-03-23 | MTBLS14116 | MetaboLights
MetabolomicsSearching for Drug Synergy Against Cancer Through Polyamine Metabolism Impairment: Insight Into the Metabolic Effect of Indomethacin on Lung Cancer Cells
Non-small cell lung cancer (NSCLC) is the most lethal and prevalent type of lung cancer. In almost all types of cancer, the levels of polyamines (putrescine, spermidine, and spermine) are increased, playing a pivotal role in tumor proliferation. Indomethacin, a non-steroidal anti-inflammatory drug, ...
2021-02-08 | MTBLS873 | MetaboLights
Sort   by:  
 Page size